The Antibody Characterization Laboratory (ACL) is the laboratory responsible for the development of well-characterized monoclonal antibody reagents. The NCI’s Office of Cancer Clinical Proteomics Research funds ACL as a resource to the entire cancer research community. ACL produces monoclonal antibodies to putative cancer targets selected by an Antibody Scientific Committee, and each antibody is characterized using optimized Standard Operating Procedures (SOPs). Approximately once a year there is a reagent target request open to the extramural research community. ACL is operated by Leidos Biomedical Research Inc. on behalf of NCI as part of the Frederick National Laboratory.
Antibody Characterization
The ACL engages in the characterization of monoclonal antibodies using an SOP-driven set of standard assays that provide a baseline understanding of the performance of antibodies in a variety of different assays including SDS-PAGE, Western blot, ELISA, Immunohistochemistry, Immuno Mass Spectroscopy and Surface Plasmon Resonance. Antibody characterization data is publicly available at Antibody Data Portal help accelerate cancer research.
Monoclonal Antibodies and Cell Lines
Monoclonal antibodies and hybridomas are available at the Developmental Studies Hybridoma Bank for research use only and to commercial entities through non-exclusive licensing agreements for more information contact cancer.proteomics@mail.nih.gov
Immunoassay Development
ACL staff have expertise in the development of immunoassay and are available for consultation. Expertise includes Design, development, and deployment of the FDA-approved assay; cGMP design of reagents and documentation; Clinical laboratory operation and management; Antibody selection and pairing.
Established Technologies